Results 11 to 20 of about 29,702 (243)

Clinical management of patients with Cushing syndrome treated with mifepristone: consensus recommendations

Clinical Diabetes and Endocrinology, 2020
Background While surgery is the first-line treatment for patients with endogenous hypercortisolism (Cushing syndrome [CS]), mifepristone has been shown to be a beneficial medical treatment option, as demonstrated in the SEISMIC (Study of the Efficacy and
David R. Brown, Honey E. East, Bradley S. Eilerman, Murray B. Gordon, Elizabeth E. King, Laura A. Knecht, Brandon Salke, Susan L. Samson, Kevin C. J. Yuen, Hanford Yau   +9 more
doaj   +2 more sources

Mifepristone as a Potential Therapy to Reduce Angiogenesis and P-Glycoprotein Associated With Glioblastoma Resistance to Temozolomide

Frontiers in Oncology, 2020
Glioblastoma, the most common primary central nervous system tumor, is characterized by extensive vascular neoformation and an area of necrosis generated by rapid proliferation.
Monserrat Llaguno-Munive, Monserrat Llaguno-Munive, Sebastián León-Zetina, Inés Vazquez-Lopez, María del Pilar Ramos-Godinez, Luis A. Medina, Luis A. Medina, Patricia Garcia-Lopez   +7 more
doaj   +2 more sources

Advanced assessment of migration and invasion of cancer cells in response to mifepristone therapy using double fluorescence cytochemical labeling

BMC Cancer, 2019
Background Previous work in our laboratory demonstrated that antiprogestin mifepristone impairs the growth and adhesion of highly metastatic cancer cells, and causes changes in their cellular morphology.
Sabrina J. Ritch, BreeAnn N. Brandhagen, Alicia A. Goyeneche, Carlos M. Telleria   +3 more
doaj   +2 more sources

Alk-Fam150b (augmentor α) expression in the paraventricular nucleus of the mouse hypothalamus at molecular resolution, and its sensitivity to acute stress. [PDF]

J Neuroendocrinol
In this study, Laurent Gueissaz and his colleagues use cell‐resolved molecular profiling and in situ hybridization to characterize cellular underpinnings of augmentor α‐ALK signaling in the paraventricular nucleus of the mouse hypothalamus. They also show that acute stress affects the transcription of augmentor α but not ALK, which can have functional ...
Gueissaz L, Sideromenos S, Tretiakov EO, Schnell R, Harkany T.   +4 more
europepmc   +2 more sources

Effect of Mifepristone vs Placebo for Treatment of Adenomyosis With Pain Symptoms

JAMA Network Open, 2023
Key Points Question Is mifepristone effective for adenomyosis treatment? Findings In this randomized clinical trial of 134 participants with adenomyosis pain symptoms, the participants in the mifepristone group and had significantly greater improvement ...
Xuan Che, Jianzhang Wang, Wenting Sun, Jiayi He, Qiming Wang, Danyang Zhu, Weili Zhu, Jing Zhang, Jie Dong, Jingui Xu, Feiyun Zheng, Jianwei Zhou, Weidong Zhao, Qiaohong Lin, L. Ye, Xiumin Zhao, Zhengfen Xu, Yun-xiang Chen, Jing Wang, Wenlie Wu, Lingyun Zhai, Yuanyuan Zhou, Jiang-xia Zheng, Xin-mei Zhang   +23 more
semanticscholar   +1 more source

Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial

Clinical Cancer Research, 2022
Purpose: Preclinical data suggest that antiprogestins inhibit the growth of luminal breast carcinomas that express higher levels of progesterone receptor isoform A (PRA) than isoform B (PRB). Thus, we designed a presurgical window of opportunity trial to
A. Elía, L. Saldain, S. Vanzulli, L. Helguero, Caroline A. Lamb, V. Fabris, Gabriela Pataccini, Paula Martínez-Vazquez, J. Burruchaga, Ines Caillet-Bois, E. Spengler, G. Acosta Haab, M. Liguori, Alejandra Castets, S. Lovisi, M. F. Abascal, V. Novaro, Jana Sánchez, J. Muñoz, J. Belizán, M. Abba, H. Gass, P. Rojas, C.C. Lanari   +23 more
semanticscholar   +1 more source

Clinical Utility of Mifepristone: Apprising the Expanding Horizons

Cureus, 2022
Mifepristone is a progesterone and glucocorticoid receptor antagonist. Medical abortion with mifepristone and prostaglandin has revolutionized the abortion process extending abortion care to the doors of females.
Z. Karena, H. Shah, Hetvee Vaghela, Kalp Chauhan, P. Desai, A. Chitalwala   +5 more
semanticscholar   +1 more source

Abortion Safety and Use with Normally Prescribed Mifepristone in Canada.

New England Journal of Medicine, 2021
BACKGROUND In the United States, mifepristone is available for medical abortion (for use with misoprostol) only with Risk Evaluation and Mitigation Strategy (REMS) restrictions, despite an absence of evidence to support such restrictions.
L. Schummers, E. Darling, S. Dunn, K. McGrail, Anastasia Gayowsky, M. Law, T. Laba, J. Kaczorowski, W. Norman   +8 more
semanticscholar   +1 more source

Mifepristone Increases Life Span in Female Drosophila Without Detectable Antibacterial Activity

Frontiers in Aging, 2022
Mifepristone dramatically increases the life span of mated female Drosophila while reducing the expression of innate immune response genes. Previous results indicated that mifepristone also reduced the load of aero-tolerant bacteria in mated females ...
Gary N. Landis, Luke Riggan, Hans S. Bell, William Vu, Tianyi Wang, Ina Wang, Felicia I. Tejawinata, Sebastian Ko, John Tower   +8 more
doaj   +1 more source

Client satisfaction and experience of telemedicine and home use of mifepristone and misoprostol for abortion up to 10 weeks' gestation at British Pregnancy Advisory Service: a cross-sectional evaluation.

Contraception, 2021
OBJECTIVE Evaluate satisfaction and experience with telemedicine consultation and home use of mifepristone and misoprostol for abortion to 10 weeks' gestation. STUDY DESIGN Cross-sectional evaluation of British Pregnancy Advisory Service (BPAS) clients
M. Meurice, K. Whitehouse, R. Blaylock, Jenny J. Chang, P. Lohr   +4 more
semanticscholar   +1 more source